Home > Insider Trading > Filing (0000919574-19-007337)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1371217	Reshape Lifesciences Inc.	RSLS	Electromedical & Electrotherapeutic Apparatus (3845)	481293684

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1601086	Armistice Capital, Llc	510 Madison Avenue, 7Th Floor New York NY 10022	No	No	Yes	No
1633584	Ltd. Fund Master Capital Armistice	C/O Dms Corporate Services Ltd. 20 Genesis Close, P.o. Box 314 Grand Cayman E9 KY1-1104	No	No	Yes	No
1706140	Steven Boyd	C/O Armistice Capital, Llc 510 Madison Avenue, 7Th Floor New York NY 10022	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-11-14	2,200	$7.35	182,838	No	4	P	Direct
Common Stock	Acquisiton	2019-11-14	0	$0.00	182,838	No	4	P	Indirect	See Footnote 1
Common Stock	Acquisiton	2019-11-18	1,330	$5.95	184,168	No	4	P	Direct
Common Stock	Acquisiton	2019-11-18	0	$0.00	184,168	No	4	P	Indirect	See Footnote 1
Common Stock	Acquisiton	2019-11-18	205	$5.97	184,373	No	4	P	Direct
Common Stock	Acquisiton	2019-11-18	0	$0.00	184,373	No	4	P	Indirect	See Footnote 1

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Indirect	See Footnote 1
No	4	P	Direct
No	4	P	Indirect	See Footnote 1
No	4	P	Direct
No	4	P	Indirect	See Footnote 1

Footnotes

The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"). The reported securities may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of the Master Fund. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC. Armistice Capital, LLC and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
This constitutes the weighted average purchase price. The prices range from $6.88 to $7.90. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.